Targeting Endoplasmic Reticulum Stress in Human Hypertension

Part of paid clinical trials in Fort Worth, Texas.

Sponsor
University of North Texas Health Science Center
Study ID
NCT06025630
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • TUDCA — DRUG
    Endoplasmic reticulum stress will be inhibited by chronic (8 weeks) oral ingestion of the dietary supplement tauroursodeoxycholic acid (TUDCA; 1,750 mg/day)
  • Placebo — DRUG
    Placebo pills containing microcrystalline cellulose will be ingested over the course of the 8 week intervention.

Study Details

There is strong evidence suggesting that endoplasmic reticulum stress contributes to neurogenic and vascular hypertension in various animal models, however this has never been explored in humans. Therefore, this project will fill this gap by performing a single-blind, placebo-controlled trial in humans with hypertension.

Key Dates

Start date
Aug 15, 2023
Status verified
Mar 2025
Primary completion
Dec 31, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
70 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Endoplasmic Reticulum Stress Inhibition
  • Placebo Comparator: Placebo

Primary Outcome Measure

24 hour Blood Pressure [ Time Frame: Within 1-2 weeks before and after intervention or placebo ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of North Texas Health Science CenterFort WorthTexas76107
Steven A Romero, PhD
[email protected]
8177355159
Bella Ruiz, BS
[email protected]
8177352088

Find similar trials in Fort Worth, TX

By condition
Hypertension (high blood pressure)
By specialty
CardiologyHeart disease
By research site
University of North Texas Health Science Center· Fort Worth, TX

Related Studies